Wall Street brokerages expect that STERIS plc (NYSE:STE) will post $780.57 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for STERIS’s earnings. The highest sales estimate is $790.00 million and the lowest is $770.00 million. STERIS posted sales of $774.26 million during the same quarter last year, which would indicate a positive year over year growth rate of 0.8%. The company is expected to announce its next earnings results on Monday, February 8th.

On average, analysts expect that STERIS will report full year sales of $3.06 billion for the current financial year, with estimates ranging from $3.03 billion to $3.09 billion. For the next year, analysts anticipate that the business will report sales of $3.30 billion, with estimates ranging from $3.25 billion to $3.38 billion. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover STERIS.

STERIS (NYSE:STE) last announced its earnings results on Monday, November 2nd. The medical equipment provider reported $1.48 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.27 by $0.21. The business had revenue of $756.13 million for the quarter, compared to analyst estimates of $719.54 million. STERIS had a return on equity of 16.24% and a net margin of 13.69%. STERIS’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm earned $1.32 EPS.

Several equities analysts have weighed in on the company. Stephens lifted their price objective on STERIS from $170.00 to $200.00 in a report on Wednesday, October 7th. JMP Securities lifted their price objective on STERIS from $180.00 to $200.00 in a report on Thursday, October 8th. Robert W. Baird lifted their price objective on STERIS from $175.00 to $200.00 and gave the company an “outperform” rating in a report on Wednesday, October 7th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a report on Friday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $189.50.

Shares of NYSE STE opened at $196.05 on Thursday. The stock has a market capitalization of $16.73 billion, a PE ratio of 40.76 and a beta of 0.66. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.29 and a quick ratio of 1.71. The business has a fifty day moving average price of $184.96 and a two-hundred day moving average price of $164.53. STERIS has a fifty-two week low of $105.69 and a fifty-two week high of $196.80.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 18th. Stockholders of record on Tuesday, November 24th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Monday, November 23rd. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.82%. STERIS’s dividend payout ratio (DPR) is currently 28.37%.

In other STERIS news, CAO Karen L. Burton sold 4,602 shares of the company’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $179.42, for a total value of $825,690.84. Following the sale, the chief accounting officer now owns 10,746 shares in the company, valued at approximately $1,928,047.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Walter M. Rosebrough, Jr. sold 10,000 shares of the company’s stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $181.39, for a total value of $1,813,900.00. Following the sale, the chief executive officer now owns 71,405 shares in the company, valued at approximately $12,952,152.95. The disclosure for this sale can be found here. Insiders have sold a total of 58,602 shares of company stock valued at $9,783,141 in the last three months. 1.20% of the stock is owned by insiders.

Several institutional investors have recently made changes to their positions in STE. Advisor Partners LLC boosted its stake in STERIS by 8.8% in the third quarter. Advisor Partners LLC now owns 2,095 shares of the medical equipment provider’s stock valued at $367,000 after acquiring an additional 169 shares in the last quarter. Paces Ferry Wealth Advisors LLC acquired a new stake in STERIS in the third quarter valued at approximately $30,000. Chiron Investment Management LLC boosted its stake in STERIS by 61.5% in the third quarter. Chiron Investment Management LLC now owns 1,050 shares of the medical equipment provider’s stock valued at $185,000 after acquiring an additional 400 shares in the last quarter. Voloridge Investment Management LLC acquired a new stake in STERIS in the third quarter valued at approximately $1,776,000. Finally, Worldquant Millennium Advisors LLC acquired a new stake in STERIS in the third quarter valued at approximately $2,162,000. Institutional investors own 89.97% of the company’s stock.

STERIS Company Profile

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.

Recommended Story: What is the Moving Average Convergence Divergence (MACD) oscillator?

Get a free copy of the Zacks research report on STERIS (STE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for STERIS (NYSE:STE)

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.